Berry Genomics Co Ltd (000710) fair value: what the stock is really worth
As of Sep 30, 2026: fair value of Berry Genomics Co Ltd ¥1.35, price ¥10.87, upside -87.6%, quality 45 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Berry Genomics Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range ¥5.99 – ¥34.86 · fair‑value band ¥1.17 – ¥1.52 · the ¥10.87 price screens above the ¥1.35 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Berry Genomics Co in your weekly email
Every Wednesday you see whether Berry Genomics Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Berry Genomics Co.,Ltd, a genomics and life science company, develops and commercializes of genetic test technologies in clinical applications in China. The company offers non-invasive DNA prenatal testing service, genetic disease testing, tumor genetic testing, NextSeq CN500 gene sequencer, and laboratory solutions.
Show more
Berry Genomics Co.,Ltd, a genomics and life science company, develops and commercializes of genetic test technologies in clinical applications in China. The company offers non-invasive DNA prenatal testing service, genetic disease testing, tumor genetic testing, NextSeq CN500 gene sequencer, and laboratory solutions. It also provides technology services, such as human genome sequencing, transcriptional regulation, single cell/spatial sequencing, animal and plant genome resequencing, genome denovo sequencing, and microbial sequencing, as well as big data services. The company serves various organizations and facilities, including hospitals, research institutions, universities, and enterprises throughout Mainland China, Hong Kong, Macao, Taiwan, Southeast Asia, the Middle East, and Australia. The company was founded in 2010 and is headquartered in Beijing, China.
Stock analysis
Berry Genomics Co Ltd (000710) currently trades at ¥10.87, while our model-based Fair Value estimate is ¥1.35, 87.6% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 2 models at a data quality of 93/100, which puts the evidence level at low.
Scenario range: ¥1.17 (bear) to ¥1.52 (bull), the price of ¥10.87 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Berry Genomics Co Ltd reported revenue of 930M CNY in FY2025 versus 1.4B CNY in FY2021, a compound −10.1%/yr. Reported net income was −197M CNY in FY2025.
Key figures
Market cap 3.8B CNY (≈ $574M) · P/S ratio 3.05 · EPS (TTM) ¥−0.6000 · Dividend yield 0.2% · Net margin −21.2% · Return on equity −13.1% · Return on assets (EBIT) −7.7% · Operating margin −7.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 28% below its 52-week high and 47% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −6% fair-value upside, at −88%, 000710 screens richer than that median.
Fair Value models
Bear ¥1.17Fair Value ¥1.35Bull ¥1.52
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−13.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−12.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−9.6%
Start year 2020 (pandemic). Over 10 years: +7.6% a year
Revenue growth 31 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
15.9% (2020) → −7.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 136 stocks
Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score46 · Below median
Fair Value upside−87.6% · Bottom 25%
Profitability
Return on assets−5.1% · Bottom 25%
Net margin (TTM)−22.8% · Bottom 25%
Operating margin (TTM)−7.2% · Bottom 25%
Growth and dividend
Revenue growth−3.5% · Below median
Dividend yield (TTM)0.2% · Bottom 25%
Balance sheet
Debt / equity0.03× · Below median
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
P/B0.39× · Cheapest 25%
P/S (TTM)0.62× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 28
PAST (return on equity)0· sector 10
HEALTH (low debt)99· sector 93
DIVIDEND (yield)3· sector 30
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Berry Genomics Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/000710
Frequently asked questions
Is Berry Genomics Co Ltd (000710) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ¥1.35 versus a price of ¥10.87, about −88% upside (overvalued).
What is the fair value of 000710?
Our model-based fair value for Berry Genomics Co Ltd is ¥1.35 (as of Sep 24, 2026), built from audited fundamentals. The current price: ¥10.87.
What is the quality score of 000710?
Berry Genomics Co Ltd has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Berry Genomics Co Ltd (000710)?
Our model-based price target is the fair value of ¥1.35 (as of Sep 24, 2026) from 2 valuation models. Cautious scenario ¥1.17, optimistic scenario ¥1.52. It is a calculation from audited fundamentals, not an analyst target.
What is the Berry Genomics Co Ltd stock forecast for 2026?
Our models put fair value at ¥1.35, about −88% upside versus a price of ¥10.87 (overvalued). Cautious scenario ¥1.17, optimistic scenario ¥1.52. The calculation is refreshed regularly with new filings.
What is the revenue of Berry Genomics Co Ltd (000710)?
Berry Genomics Co Ltd reported trailing-twelve-month revenue of about 922M CNY (latest available figure, as of Sep 24, 2026).
Does Berry Genomics Co Ltd pay a dividend?
Berry Genomics Co Ltd currently shows a dividend yield of about 0.17% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Berry Genomics Co Ltd (000710)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Berry Genomics Co Ltd it is ¥1.35 per share (as of Sep 24, 2026), against a price of ¥10.87. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is Berry Genomics Co Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 000710 trades above its calculated fair value: price ¥10.87, fair value ¥1.35, a gap of about −88% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 000710?
No. The price is what the market pays today (¥10.87); the fair value is what the company's own numbers justify (¥1.35). For Berry Genomics Co Ltd the two are ¥9.52 per share apart. That gap is exactly why we show both numbers side by side.
How much is Berry Genomics Co Ltd worth?
The market values Berry Genomics Co Ltd at about 3.8B CNY (market capitalisation, as of Sep 24, 2026). Per share that is ¥10.87; our models calculate a fair value of ¥1.35 per share.
What do the bullish and bearish scenarios say about 000710?
Our models span a range for Berry Genomics Co Ltd: cautious scenario ¥1.17, base ¥1.35, optimistic ¥1.52 per share (as of Sep 24, 2026, price ¥10.87). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Berry Genomics Co Ltd (000710)?
Balance-sheet figures for Berry Genomics Co Ltd (as of Sep 24, 2026): return on equity −13.1%, debt of 0.03 per unit of equity. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is 000710 from its 52-week high?
Berry Genomics Co Ltd trades at ¥10.87, about 28% below its 52-week high of ¥15.00 and 47% above the low of ¥7.37 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of ¥1.35 is for.
Which stocks are comparable to Berry Genomics Co Ltd?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Agilent Technologies, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Berry Genomics Co Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price ¥10.87, calculated fair value ¥1.35 (−88%), Quality Score 45/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 000710 calculated?
We run Berry Genomics Co Ltd through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥1.35, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Berry Genomics Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Berry Genomics Co Ltd (000710)?
The closing price on Sep 30, 2026 was ¥10.87. Our model-based fair value is ¥1.35, about −88% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Berry Genomics Co Ltd right now?
The price sits above even our optimistic bull case (¥1.52). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (45/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Berry Genomics Co Ltd
How large is the market capitalisation of Berry Genomics Co Ltd (000710)?
The market capitalisation of Berry Genomics Co Ltd is 3.8B CNY (≈ $574M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Berry Genomics Co Ltd (000710)?
The price-to-sales ratio of Berry Genomics Co Ltd is 3.05 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Berry Genomics Co Ltd (000710)?
Earnings per share at Berry Genomics Co Ltd are ¥−0.6000. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Berry Genomics Co Ltd (000710)?
The dividend yield of Berry Genomics Co Ltd is 0.2%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Berry Genomics Co Ltd (000710)?
The net margin of Berry Genomics Co Ltd is −21.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Berry Genomics Co Ltd (000710)?
The return on equity (ROE) of Berry Genomics Co Ltd is −13.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Berry Genomics Co Ltd (000710)?
On an EBIT basis the return on assets of Berry Genomics Co Ltd is −7.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Berry Genomics Co Ltd (000710)?
The operating margin of Berry Genomics Co Ltd is −7.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Berry Genomics Co Ltd (000710)?
Revenue at Berry Genomics Co Ltd is growing −3.5% versus a year earlier (3y avg −12.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Berry Genomics Co Ltd (000710)?
Earnings per share at Berry Genomics Co Ltd are growing −82.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Berry Genomics Co Ltd (000710) generate?
The free cash flow of Berry Genomics Co Ltd is −5.1M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Berry Genomics Co Ltd (000710) hold?
Berry Genomics Co Ltd holds more cash than debt, 226M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Berry Genomics Co Ltd in the live analysis
One click puts Berry Genomics Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
